StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Kunal Parar, Choice Broking

BUYZydus Lifesciences Limited

byKunal Parar, Choice BrokingHorizon: NA (inferred Swing (≤2wk))25 Sept 2026via ET Now (Live)

Entry₹1,198.3Inferred
Target₹1,240
Total upside +3.48%
Stop loss₹1,150-4.03% risk
CMP₹1,203.91d ago
Active+0.47%+3.00%upside left 12d left
Follow Kunal Parar for new calls(27% target hit, 52 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 3 other Swing calls on ZYDUSLIFESee 311 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 27 Sept, 2:05 pm IST
6 supporting1 neutral1 opposing
Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·27 Sept · today

Zydus Lifesciences says USFDA inspection at New Jersey office concludes with nil observations

NewsCnbc-Tv18·26 Sept · yesterday

(opens in new tab)

The USFDA inspection of Zydus Lifesciences' USA office for pharmacovigilance and post-marketing systems concluded with no observations.

BSE · Company Update·26 Sept · yesterday

(opens in new tab)

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·25 Sept · 2d ago

Bernstein bets on this drugmaker for 28% upside citing a key value driver for the future

NewsCnbc-Tv18·18 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Zydus Lifesciences (NSE:ZYDUSLIFE): Why Did It Publish a Lost Share Certificate Notice?

NewsGoogle News·24 Sept · 2d ago

(opens in new tab)
Weighs against the BUY call (1)

RSI at 71 — overbought territory

Technicals · rsi·27 Sept · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.